Ascendis Pharma A/S
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 14
- Market Cap
- $7.9B
- Introduction
Ascendant Resources Inc is a mining company. The company is engaged in evaluating resource opportunities. The Company’s sole investment and exploration activities are in the Lagoa Salgada Project in Portugal. It is focused on its own producing El Mochito zinc, silver and lead mine. The El Mochito mine is located in northwestern Honduras. The underground operation takes advantage of selective and bulk underground mining methods to mine multiple flat-lying manto deposits and high-grade vertical chimneys, producing zinc and lead concentrates with silver credits.
Clinical Trials
22
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for navepegritide
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 24
- Registration Number
- NCT06732895
- Locations
- 🇫🇷
Ascendis Investigational Site, Paris, France
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for TransCon CNP
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05246033
- Locations
- 🇨🇳
Ascendis Pharma Investigational Site, Wuhan, China
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for TransCon CNP
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 57
- Registration Number
- NCT04085523
- Locations
- 🇵🇹
Ascendis Pharma Investigational Site, Coimbra, Portugal
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism
- Conditions
- HypoparathyroidismEndocrine System DiseasesParathyroid Diseases
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 59
- Registration Number
- NCT04009291
- Locations
- 🇳🇴
Ascendis Pharma Investigational Site, Oslo, Norway
A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
- Conditions
- Achondroplasia
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 260
- Registration Number
- NCT03875534
- Locations
- 🇬🇧
Ascendis Pharma Investigational Site, London, United Kingdom
- Prev
- 1
- 2
- Next
News
TransCon PTH Demonstrates Sustained Skeletal Benefits in Hypoparathyroidism Patients: 3-Year Data
Ascendis Pharma's TransCon PTH (palopegteriparatide) normalized bone remodeling in adults with hypoparathyroidism after 162 weeks of treatment.